14 JUNE AUDITORIUM 2000

8:30 – 10:00 Registration & Coffee

10:00 – 12:30 Morning session
Keynote presentations

- Welcome and introduction
  *Michel Goldman*, Executive Director IMI

- Reshaping biopharmaceutical research in Europe
  *Roch Doliveux*, Chief Executive Officer UCB

- Public-Private Partnerships in the Health sector: the EU perspective
  *Philippe Cupers*, DG Research, European Commission

- Q&A

10:45 - 11.15 Coffee break

- How to accelerate approval of innovative drugs
  *Bruno Flamion*, European Medicines Agency EMA

- Patients' expectations
  *Nicola Bedlington*, Director European Patients' Forum

- Opportunities for research organisations
  *Stavros Malas*, Chair States Representatives Group

- Achievements and challenges ahead
  *Michel Goldman*, Executive Director IMI

- Q&A

12:30 – 14:00: Lunch Break
Lunch + networking

14:00 – 17:00: Afternoon sessions
Four parallel workshops: ongoing IMI projects (1st Call) – first results
14 JUNE (CONTINUED)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 – 17:00</td>
<td>Thematic workshops (parallel)</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>Coffee Break</td>
</tr>
</tbody>
</table>

**WORKSHOP 1: DRUG SAFETY  AUDITORIUM 500  Moderator: Maria-Teresa de Magistris**

- **eTOX:** Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities  
  *Ferran Sanz, Fundació IMIM*
- **SAFE-T:** Clinical biomarker qualification via safer and faster evidence-based translation  
  *Michael Merz, Novartis*
- **PROTECT:** Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium  
  *Xavier Kurz, European Medicines Agency*
- **MARCAR:** bioMARkers and molecular tumor classification for nongenotoxic CARcinogenesis  
  *Jonathan Moggs, Novartis*

**WORKSHOP 2: NEUROSCIENCES  AUDITORIUM 2000  Moderator: Elisabetta Vaudano**

This session (and only this one) starts at 14:30

- **PHARMA-COG:** Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development.  
  *Alexandra Auffret, University of Marseille*
- **NEWMEDS:** Novel Methods leading to New Medications in Depression and Schizophrenia  
  *Tine Bryan Stensbøl, H. Lundbeck*
- **EUROPAIN:** Understanding chronic pain and improving its treatment  
  *Märta Segerdahl, AstraZeneca*

**WORKSHOP 3: TRAINING  ROOM 1121  Moderator: Fatiha Sadallah**

- **Eu2P:** European programme in Pharmacovigilance and Pharmacoepidemiology  
  *Deborah Szafir, F. Hoffmann – La Roche*
- **EMTRAIN:** European Medicines Research Training Network  
  *Mike Hardman, AstraZeneca*
- **SAFESCI MET:** European Modular Education and Training Programme in Safety Sciences for Medicines  
  *Theodor Guentert, F. Hoffmann - La Roche*
- **PHARMATRAIN:** Pharmaceutical Medicine Training Programmes  
  *Fritz Buhler, University of Basel*

**WORKSHOP 4: DIABETES & LUNG DISEASE  ROOM 1122  Moderator: Ann Martin**

- **U-BIOPRED:** Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes  
  *Chris Compton, Novartis*
- **PROACTIVE:** Physical Activity as a crucial Patient Reported Outcome in COPD: ‘PROactive’  
  *Thierry Troosters, Katholieke Universiteit Leuven*
- **IMIDIA:** Improving beta-cell function and identification of diagnostic biomarkers for treatment monitoring in diabetes  
  *Bernard Thorens, Université de Lausanne & Alain Ktorza, Institut de Recherches Servier*
- **SUMMIT:** Surrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools  
  *Leif Groop, Lund University & Michael Mark, Boehringer Ingelheim*

17:00-18:00 Closing Coffee
15 JUNE

8:30 – 9:30 Registration & Coffee

9:30 – 12:30 Morning Session: The Future of IMI Auditorium 2000

- Lessons learnt
  Michel Goldman, Executive Director IMI

- The 3rd Call for proposals (2010)
  Titta Rosvall-Puplett, Director Research Directors Group, EFPIA

- New ways of sharing knowledge
  Magali Poinot, Legal Manager IMI

10:45 – 11:15 Coffee break

- Revision of the IMI scientific strategy:
  Towards a new Research Agenda
  Christian Noë, chair of the Scientific Committee

- Round table Q&A
  Introduction: Michel Goldman, Executive Director IMI
  Panelists: Michel Goldman, Magali Poinot, Christian Noë, Titta Rosvall-Puplett

12:30 – 14:00 Farewell Lunch